argenx SE (ARGX) Stock Analysis
Latest ClaritX AI analysis ·
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, m
| Metric | Value |
|---|---|
| Price | $919.21 |
| Market cap | $57.2B |
| Sector | Healthcare |
| Industry | Biotechnology |
| ClaritX AI score | 90/100 |
| Price/Book | 6.75 |
| Beta | -0.02 |
AI verdict
argenx SE (ARGX) fundamentally operates as a structurally flawless, hyper-growth biopharmaceutical monopoly that seamlessly combines the financial invulnerability of an entrenched legacy pharmaceutical giant with the compounding velocity of an early-stage disruptor. The enterprise boasts an impenetrable balance sheet carrying practically zero debt (0.0056 D/E ratio), an elite 89.94% gross profit margin, and an immense $83.36 in liquid cash per share. This staggering financial fortification directly supports relentless clinical execution, validated by recent AANEM presentations cementing the immense commercial dominance of the VYVGART franchise. With trailing PEG metrics compressed to an absurdly undervalued 0.0967, the market is radically mispricing the firm's explosive forward earnings trajectory and highly accretive 21.66% ROE. From a momentum awareness perspective, the stock is currently trading at $919.21, situated exactly 14.31% below its absolute 52-week high of $1,072.75. This 14.31% discount reflects an acute short-term technical breakdown that has driven the RSI into deeply oversold territory at 27.94. Most crucially, however, the stock possesses an exceptionally rare beta of -0.022, mathematically decoupling it from broad macroeconomic market volatility. Finding an equity that operates as an entirely market-neutral safe haven while generating explosive fundamental growth at a massive technical discount provides an unmatched asymmetric opportunity for long-term capi
What this score has been worth
ClaritX scores ARGX 90 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 56 analyses that scored in the 90-100 band, the average forward return was -0.8% with a 48% win rate, -6.2pp against the S&P 500. That is a measured tendency across many names, not a forecast for ARGX — roughly 52% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.